on November 21, 2018 by guest
|
|
- Caroline Wheeler
- 5 years ago
- Views:
Transcription
1 JOURNAL OF VIROLOGY, Oct. 1998, p Vol. 72, No X/98/$ Copyright 1998, American Society for Microbiology. All Rights Reserved. Local Periocular Vaccination Protects against Eye Disease More Effectively Than Systemic Vaccination following Primary Ocular Herpes Simplex Virus Infection in Rabbits ANTHONY B. NESBURN, 1,2 * SUSAN SLANINA, 1 RAE LYN BURKE, 3 HOMAYON GHIASI, 1,2 S. BAHRI, 1 AND STEVEN L. WECHSLER 1,2 Ophthalmology Research Laboratories, Cedars-Sinai Medical Center 1 and Department of Ophthalmology, UCLA School of Medicine, 2 Los Angeles, and Chiron Corp., Emeryville, 3 California Received 4 February 1998/Accepted 2 July 1998 Vaccination of experimental animals can provide efficient protection against ocular herpes simplex virus type 1 (HSV-1) challenge. Although it is suspected that local immune responses are important in protection against ocular HSV-1 infection, no definitive studies have been done to determine if local ocular vaccination would produce more efficacious protection against HSV-1 ocular challenge than systemic vaccination. To address this question, we vaccinated groups of rabbits either systemically or periocularly with recombinant HSV-2 glycoproteins B (gb2) and D (gd2) in MF59 emulsion or with live KOS (a nonneurovirulent strain of HSV-1). Three weeks after the final vaccination, all eyes were challenged with McKrae (a virulent, eye disease-producing strain of HSV-1). Systemic vaccination with either HSV-1 KOS or gb2/gd2 in MF59 did not provide significant protection against any of the four eye disease parameters measured (conjunctivitis, iritis, epithelial keratitis, and corneal clouding). In contrast, periocular vaccination with gb2/gd2 in MF59 provided significant protection against conjunctivitis and iritis, while ocular vaccination with live HSV-1 KOS provided significant protection against all four parameters. Thus, local ocular vaccination provided better protection than systemic vaccination against eye disease following ocular HSV-1 infection. Since local vaccination should produce a stronger local immune response than systemic vaccination, these results suggest that the local ocular immune response is very important in protecting against eye disease due to primary HSV-1 infection. Thus, for clinical protection against primary HSV-1-induced corneal disease, a local ocular vaccine may prove more effective than systemic vaccination. Downloaded from Human herpes simplex virus (HSV) infections are common, occur at diverse sites, and have a wide range of symptoms, from inapparent to life-threatening encephalitis (2, 3). HSV infects mucosal surfaces, most commonly producing infections of the genitals, the mouth, or the eye. Greater than 90% of ocular HSV infections are due to HSV type 1 (HSV-1). HSV-1 infection of the eye can produce corneal inflammation and scarring as the result of an incompletely defined immunological response to the virus (1, 7, 14, 27, 32). This scarring is a major cause of corneal blindness (22, 35). In developed nations, HSV is the most frequent serious viral eye infection and is the most common cause of infectious blindness (22). In the United States, almost 500,000 people per year suffer primary or recurrent ocular HSV episodes that require doctor visits and medication (22). Over 1,000 corneal transplants per year are done in the United States as a direct result of HSV scarring (22, 35). Experimental primary and recurrent ocular HSV-1 infection in the rabbit and the naturally occurring infection in humans share many characteristics. Primary infection is self-limited and is characterized by a benign transient infectious conjunctivitis. Infection of the cornea starts with epithelial keratitis, which destroys the corneal epithelium in a characteristic dendritic (neuron-like) and later geographic (amoeboid-like) pattern. As the keratitis, and its accompanying virus-induced immune-mediated inflammation, spread to the deeper part of the cornea (the stroma), the cornea becomes (temporarily) cloudy. * Corresponding author. Mailing address: Ophthalmology Research Laboratories, Cedars-Sinai Medical Center, Davis Bldg., Room 5069, 8700 Beverly Blvd., Los Angeles, CA Phone: (310) Fax: (310) wechsler@csmc.edu. Iritis (inflammation of the iris and anterior chamber) usually occurs only in eyes with severe keratitis. Corneal clouding and iritis follow, and are less common than, epithelial keratitis. In the rabbit, as in humans, HSV-1 epithelial keratitis with its dendritic and geographical spread is the hallmark of herpetic corneal infection. In fact, clinically, the dendritic ulcer is pathognomonic (i.e., characteristic or symptomatic of a particular disease) and requires no laboratory confirmation for the diagnosis of HSV infection. Epithelial keratitis is therefore the most relevant and important eye disease parameter in the studies described in this report. The only Food and Drug Administration-approved treatments for primary HSV-1 ocular infection consist of the topical antivirals idoxuridine, vidarabine, and trifluorothymidine as well as oral acyclovir. Outside the United States, topical acyclovir is also used. Until recently, little attention has been given to the development of a vaccine against ocular HSV-1 infection. Virtually all work on HSV vaccine development has focused on the problem of genital HSV-2. Well-defined herpesvirus glycoprotein subunit vaccines have been developed by using recombinant DNA technology. These vaccines afford protective immunity when used prophylactically in mouse and guinea pig models of HSV-1 and HSV-2 disease (2, 8 11, 34, 36, 37). Local immunity is likely to be especially important for mucosal surfaces such as the eye. In addition, previous HSV-1 infection at a nonocular site does not protect against nonprimary first episodes of ocular HSV-1 (4) or against recurrent ocular HSV-1 infection. Therefore, it was of interest to determine if ocular vaccine administration would be more effective than systemic vaccine administration as prophylaxis against on November 21, 2018 by guest 7715
2 7716 NESBURN ET AL. J. VIROL. primary infection and the resulting eye disease in rabbits following ocular challenge with a highly pathogenic HSV-1 strain (McKrae). Two different vaccines, both expected to be less than optimal, were used. Both vaccines afforded protection against lethal ocular challenge regardless of the route of administration. However, neither vaccine provided any protection against ocular disease when administered systemically. In contrast, both vaccines provided protection against ocular disease when administered periocularly, thus supporting the notion that ocular immunity is more important than systemic immunity in protecting against eye disease. MATERIALS AND METHODS FIG. 1. Survival of vaccinated rabbits following ocular challenge with HSV-1 McKrae. Rabbits were vaccinated either i.m. or ocularly with either gb2/gd2 or HSV-1 KOS as described in Materials and Methods. The mock-vaccinated control (Cont) group was vaccinated i.m. with adjuvant alone. Three weeks after the final vaccination, all rabbits were challenged with PFU of HSV-1 McKrae in both eyes as described in Materials and Methods. Survival was determined 3 weeks after challenge. The ratio above each bar shows the number of surviving rabbits/the number of challenged rabbits. Comparisons were done as follows: periocular HSV-1 KOS group versus mock control group (P [Fisher exact test]; systemic HSV-1 KOS group versus mock control group (P 0.002); periocular gb2/gd2 versus mock (P 0.054); systemic gb2/gd2 versus mock (P 0.14); combined gb2/gd2 groups versus mock (P [doublesided Fisher exact test]; P 0.02 [single-sided Fisher exact test]). Virus. The challenge virus, HSV-1 McKrae, produces severe ocular disease in rabbits (25). The live-virus vaccine strain, HSV-1 KOS, is nonvirulent and produces no significant ocular disease in rabbits. Both viruses were triple plaque purified and prepared as previously described (25). Rabbits. Eight to ten-week-old New Zealand White male rabbits (Irish Farms) were used for all experiments. Rabbits were housed and handled in accordance with Association for Research in Vision and Ophthalmology, American Association for Laboratory Animal Care, and National Institutes of Health guidelines. Glycoproteins and adjuvant for subunit vaccine. HSV-2 glycoproteins B (gb2) and D (gd2) were prepared by expression of the modified genes in Chinese hamster ovary cells followed by purification to near homogeneity, using a series of traditional chromatographic steps as previously described and as previously used by Chiron Corp. in human clinical trials of a vaccine for genital herpes (20). The adjuvant MF59 was prepared as previously described (23). The vaccine was prepared by mixing 1 volume of gb2 plus gd2 in 2 phosphate-buffered saline with 1 volume of MF59. Systemic vaccination. Rabbits received three inoculations at 3-week intervals. Each inoculation with gb2/gd2/mf59 was delivered by a single intramuscular (i.m.) injection on one side of the lower back. Each dose contained 25 g of each glycoprotein in a total volume of 0.1 ml. Three systemic vaccinations with live HSV-1 KOS were given intradermally 3 weeks apart. Each intradermal vaccine dose was divided into four or five 0.1-ml aliquots and was injected into separate sites on the back for a total dose of PFU of live HSV-1 KOS. Control vaccine. The control vaccine was the adjuvant MF59 without glycoprotein (1 volume of MF59 plus 1 volume of 2 PBS) and was delivered identically and on the same schedule as the gb2/gd2/mf59 systemic vaccine. Subconjunctival vaccinations with the gb2/gd2 vaccine. Inoculations were given as previously described (23), with each eye receiving three inoculations at 3-week intervals. Each inoculation contained 7.5 g of each glycoprotein in 0.1 ml. Vaccination resulted in approximately 25% of the eyes showing mild to moderate conjunctival inflammation for up to 7 days. Topical ocular vaccination with HSV-1 KOS. Eyes were vaccinated twice at a 3-week interval with PFU of live KOS per eye as described below for HSV-1 challenge with McKrae. Since KOS produces no stromal keratitis and requires corneal scarification to produce epithelial keratitis (17, 26a, 38), the method used for inoculating with KOS resulted in no clinically recognizable disease. Ocular challenge of rabbit eyes with HSV-1 McKrae. Vaccinated and mockvaccinated rabbits were bilaterally infected without scarification or anesthesia by placing PFU (HSV-1 McKrae), in a total volume of 0.1 ml, into the conjunctival cul-de-sac, closing the eye, and rubbing the lid gently against the eye for 30 s (31). In naive rabbits, this dose of virus infects all eyes and produces moderate to severe ocular disease in about 90% of eyes. It results in the death of approximately 30 to 50% of the rabbits within 18 days (23, 25, 29, 30). Animals were challenged 3 weeks following the final dose of vaccine. Measurement of titers. HSV serum neutralizing antibody titers were measured as previously described (21), using an HSV-2 plaque reduction neutralization assay in the presence of added complement with twofold serum dilutions. The reported titer is the reciprocal of the serum dilution required to inhibit the cytolysis of a confluent monolayer of Vero cells by 50%. HSV serum enzyme-linked immunosorbent assay (ELISA) titers were determined as described previously (21), using threefold serial dilutions of serum and either recombinant gb2 or recombinant gd2 as the capture antigen. The reported titers correspond to the reciprocal of the serum dilution producing an absorbance value of 1.0. ELISA titers are antigen specific, as shown by the absence of a measurable gd or gb ELISA titer in sera obtained before immunization of animals. HSV tear ELISA titers. Tears were collected with a microcapillary pipette, and tear soluble immunoglobulin A (siga) ELISAs were performed as described above, using recombinant gd2 as the capture antigen. Determination of clinical eye disease. Clinical eye disease patterns were determined by examining the rabbit eyes in a masked fashion on days 3, 5, 7, 10, and 14 postinfection for scoring the incidence and severity of conjunctivitis, iritis, dendritic and geographic ulcers characteristic of HSV (epithelial keratitis), and acute transient stromal keratitis and edema (corneal clouding). Epithelial keratitis was evaluated by slit lamp biomicroscopy using 0.75% fluorescein stain (26). Conjunctivitis was determined by direct visual observation. The magnitude of epithelial disease was scored as 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, or 4, with 0, 1, 2, 3, and 4 representing no disease and disease involving 25, 50, 75, and 100% of the corneal surface, respectively. The levels of inflammatory severity of conjunctivitis, iritis, and stromal keratitis were assessed by using the same scale, with 0, 1, 2, 3, and 4 representing no inflammation, mild but recognizable inflammation, moderate easily recognizable inflammation, moderately severe inflammation, and very severe inflammation, respectively. To eliminate bias, these gradings were done in a masked fashion by readers highly experienced in this system. Statistical analyses. Statistical analyses were performed with Instat, a personal computer software program. Tests included the Student t test and the Fisher exact test. RESULTS Groups of naive rabbits were vaccinated either systemically or periocularly with either a gb2/gd2 subunit vaccine or live KOS, a nonvirulent HSV-1 strain that produces no eye disease in rabbits. The five experimental groups were as follows: KOS ocular vaccine, 11 rabbits; KOS systemic vaccine, 15 rabbits; gb2/gd2 ocular vaccine, 15 rabbits; gb2/gd2 systemic vaccine, 15 rabbits; and control (systemic adjuvant), 16 rabbits. Protection against mortality. Three weeks after the final vaccination, rabbits were ocularly challenged with HSV-1 McKrae. Protection against mortality was similar for each vaccine, regardless of the vaccination route (Fig. 1). The KOS vaccines were significantly more efficacious than the control (P [ocular] and [systemic]; Fisher exact test). Survival in the individual gb2/gd2 vaccine groups was not significantly more than for controls (P 0.14 [systemic] and [ocular]; Fisher exact test). However, since the two gb2/ gd2 vaccine groups were similar, the data could be combined to increase the power of the analysis. This resulted in significant protection compared to mock vaccination (P 0.036; Fisher exact test).
3 VOL. 72, 1998 PERIOCULAR VACCINATION AGAINST OCULAR HSV FIG. 2. Protection against eye disease. Rabbits were vaccinated three times either systemically or periocularly, and ocularly challenged, and eye disease was monitored on days 3, 5, 7, 10, and 14 as described in Materials and Methods. Each time point represents the average readings of both eyes from 11 to 16 rabbits from vaccinated or mock-vaccinated rabbits (ocular KOS vaccine, 11 rabbits; systemic KOS vaccine, 15 rabbits; ocular gb2/gd2 vaccine, 15 rabbits; systemic gb2/gd2 vaccine, 15 rabbits; adjuvant control, 16 rabbits). Single asterisks indicate points that are significantly less than for the mock-vaccinated control group at the 95% level, using the Student t test; double asterisks indicate values for the periocular vaccine group that are significantly less than values for the corresponding systemic vaccine group. Statistical analyses were done on a per-rabbit basis. Thus, the readings from both eyes were averaged for each rabbit, and the resulting value for each rabbit was used for the analyses (i.e., n for each group was the number of rabbits, not the number of eyes, in the group). The same groups showed statistical significance when analyses were done on a per-eye basis (not shown). Protection against conjunctivitis. No differences in the average severity of conjunctivitis were observed between mockvaccinated rabbits and rabbits vaccinated systemically with gb2/gd2 or KOS on any of the days examined (Fig. 2A) (P 0.05; Student t test). In contrast to systemic vaccination, when the route of vaccination was periocular, both the subunit gd2/ gb2 and the live KOS vaccines appeared to provide protection against conjunctivitis. In rabbits vaccinated ocularly with KOS, the average peak severity of conjunctivitis (day 5 following ocular challenge) was significantly less than in the control rabbits and in rabbits systemically vaccinated with KOS (Fig. 2B; P and 0.004, respectively; Student t test). Rabbits vaccinated ocularly with gb2/gd2 also appeared to have less conjunctivitis than control rabbits, but the difference did not quite reach statistical significance (P 0.08; one sided). However, the gb2/gd2 ocularly vaccinated rabbits had significantly less conjunctivitis than the gb2/gd2 systemically vaccinated rabbits (Fig. 2B; P 0.008). Thus, for both vaccines, compared to systemic vaccination, ocular vaccination provided significantly more protection against conjunctivitis. Protection against acute herpetic iritis. Iritis is characterized by anterior chamber inflammation (cells and fibrin) and redness of the normally pink iris. Prophylactic systemic vaccination with gb2/gd2 or KOS did not reduce the peak severity of iritis (day 7 after ocular challenge) (Fig. 2C; P 0.05). In contrast, prior periocular vaccination with gb2/gd2 resulted in significant reductions in average iritis severity compared to control and systemic gb2/gd2 vaccination on day 7 postchallenge (Fig. 2D; P 0.02 and 0.03, respectively). Ocular vaccination with KOS also significantly reduced the peak average iritis severity compared to control and the corresponding systemic vaccination (Fig. 2D; P and 0.03, respectively). Thus, as with conjunctivitis, periocular vaccination provided much more protection against manifestations of herpetic iritis than did systemic vaccination. Protection against corneal clouding. Corneal clouding (a transient corneal edema with corneal inflammation) is a measure of stromal keratitis. Systemic vaccination with gb2/gd2 or KOS did not affect the severity of corneal clouding (Fig. 2E). Periocular vaccination with gd2/gb2 also did not lessen stromal keratitis (Fig. 2F; P 0.05). In contrast, periocular vaccination with KOS completely eliminated corneal clouding. Because of the low overall levels of corneal clouding in all groups, protection against the severity of corneal clouding by ocular KOS vaccination on the day of peak disease reached statistical significance only by a single-sided analysis (Fig. 2F; P 0.04).
4 7718 NESBURN ET AL. J. VIROL. TABLE 1. Vaccine-induced humoral immune responses Vaccine (no. of rabbits) Titer (geometric mean SD) a Neutralization b gd2 ELISA gb2 ELISA KOS ocular (10 for neutralization, 39* 18 4,768 4,630 12,617 2,945 8 for ELISA) KOS systemic (12) 101* 81 8,571 4,586 13,233 10,363 gb/gd ocular (13) ,108 9,657 20,698 11,972 gb/gd systemic (14) ,097 14,962 73,151 67,048 Adjuvant control (13) 24* 34* 16 45* 34 a Neutralization titers followed by asterisks include one or more values of 24, the baseline of the assay. For the purpose of determining the mean and for statistical analyses (Table 2), 24 was substituted for 24. ELISA titers followed by asterisks include one or more values of 30, the baseline of that assay. For the purpose of determining the mean and for statistical analyses (Table 2), 30 was substituted for 30. b Neutralization assays were done against HSV-2. Comparison Protection against epithelial keratitis. HSV-1 produces corneal epithelial cell loss in a characteristic dendritic pattern. As the dendrite expands, it develops smoother edges and takes on a geographic pattern. Epithelial keratitis is the combination of these dendritic and geographic lesions. Epithelial keratitis is the key pathologic finding indicative of ocular HSV-1 infection and is the clinical hallmark of acute herpetic corneal disease. Iritis and clouding are not present without epithelial keratitis. Neither systemic gb2/gd2 nor systemic KOS vaccine provided protection against the average severity of epithelial keratitis (Fig. 2G). Local periocular vaccination with gb2/gd2 also did not provide protection against the average severity of epithelial keratitis (Fig. 2H). In contrast, periocular vaccination with KOS significantly reduced peak epithelial keratitis (Fig. 2H; P compared to control; P compared to systemic KOS vaccination). Vaccine immunogenicity. All rabbits were bled 3 weeks after the final vaccination, just prior to challenge with HSV-1. Neutralization and ELISAs (against HSV-2 and HSV-2 glycoproteins) were done individually on all sera (Tables 1 and 2). Both vaccines induced HSV-2 neutralizing antibody titers significantly greater than those for the adjuvant control, regardless of the route of vaccination (Tables 1 and 2). With both vaccines, the systemic vaccination showed a tendency to induce a higher neutralizing antibody titer than ocular vaccination, but the differences were not statistically significant. Both vaccines induced ELISA titers against gb2 and gd2 that were significantly above the control vaccine levels, regardless of the route of vaccination (Tables 1 and 2). Systemic vaccination with KOS induced an average gd2 ELISA titer significantly higher than that induced by ocular vaccination with the same vaccine. The KOS-induced gb2 ELISA titer also appeared slightly higher with systemic vaccination, but this difference was not significant. Systemic vaccination with gb2/ gd2 induced an average gb2 ELISA titer that was significantly higher than that induced by ocular vaccination with gb2/gd2. Systemic vaccination with gb2/gd2 also appeared to induce a higher ELISA titer against gd2, but this difference was not TABLE 2. Statistical analysis of data in Table 1 P value a Neutralization gd2 ELISA gb2 ELISA KOS ocular vs control KOS systemic vs control KOS ocular vs KOS systemic gb/gd ocular vs control gb/gd systemic vs control gb/gd ocular vs gbgd systemic a Determined by the Mann-Whitney rank sum test. statistically significant. Thus, systemic vaccination tended to induce stronger neutralizing antibody titers and stronger ELISA titers than ocular vaccination with the same vaccine. To examine the local ocular immune response to vaccination and challenge, groups of rabbits were vaccinated once, either periocularly or systemically, and then ocularly challenged as described above. Tear siga specific for gd2 was determined at various times by ELISAs (Fig. 3). Each point on days 3 to 21 represents the average titer of tears from 10 to 14 eyes per group. On day 3 postchallenge, the two vaccine groups were similar and had significantly more HSV-1-specific tear siga than the mock group (ocular versus mock, P [onesided Student t test]; systemic versus mock, P 0.01 [Mann- Whitney rank sum test]). This finding suggests early stimulation of a primed siga response in both vaccinated groups. There were no significant differences between the ocular and systemic vaccine groups or between either vaccine group and the mock group at any other time. However, at the time of peak HSV-1 specific tear siga response (day 10 postchallenge), there was a tendency for the mock group to have more siga than either vaccine group and for the systemic vaccine group to have more siga than the ocular vaccine group. This result was the reverse of the protective efficacy of the vaccines. DISCUSSION We previously showed that periocular vaccination of latently infected rabbits with gb2/gd2 in the adjuvant MF59/MTP-PE provided therapeutic protection against recurrent HSV-1, as judged by a statistically significant decrease in ocular spontaneous recurrent virus shedding (23) and spontaneous recurrent corneal disease (24). The present study, comparing the abilities of periocular and systemic vaccinations to protect against primary ocular HSV-1 challenge, was undertaken as part of our inquiries into the role and efficacy of periocular vaccination against primary and recurrent ocular herpes infection. The subconjunctival route used for periocular vaccination allows the use of adjuvant and ensures that the vaccine is delivered
5 VOL. 72, 1998 PERIOCULAR VACCINATION AGAINST OCULAR HSV FIG. 3. HSV-specific tear siga. Rabbits were vaccinated once, either systemically or periocularly, with gb2/gd2 and ocularly challenged 21 days later as described in Materials and Methods. Tears were collected at the times indicated, and the relative amount of HSV-1 gd2-specific siga in individual tear samples was determined by ELISA. The arrows indicate vaccination (day 21) and ocular challenge (day 0) as labeled. The asterisk indicates that both vaccine groups had significantly higher ELISA titers than the mock vaccine group (P 0.05). and retained at the local site. Subconjunctival injection is routinely used in clinical ophthalmology. In this study, two vaccines that were expected to be less than completely effective were chosen. This was done because the goal was to determine if local periocular vaccination provided better ocular protection than systemic vaccination. Obviously, a vaccine that gave 100% protection against eye disease regardless of the vaccine route would not allow us to easily determine which route was more effective. A live and a subunit vaccine were both used to determine if any route specificity found would be consistent for different types of vaccines. gb2/gd2 with MF59 was chosen as the suboptimal subunit vaccine because both glycoproteins are type 2 rather than type 1 (the McKrae challenge virus is type 1) and because the adjuvant lacks the added immunostimulant MTP-PE that was included in our recent successful therapeutic vaccine studies (23, 24). The avirulent HSV-1 KOS strain was chosen as the less than optimal live vaccine for this study because compared to other available wild-type HSV-1 strains (such as the virulent McKrae strain used as the challenge virus), its ability to replicate and spread in the rabbit is low. Thus, it was expected that HSV-1 KOS would be a suboptimal live HSV-1 vaccine. This hypothesis was supported by a small pilot study which showed that rabbits vaccinated systemically with HSV-1 McKrae, but not with HSV-1 KOS, were completely protected against eye disease (not shown). The increased vaccine efficacy of periocular compared to systemic vaccines against HSV-1-induced ocular disease (summarized in Table 3) was even more impressive, since to strengthen the likelihood that any increased protection observed with ocular vaccination would be meaningful, the vaccinations were biased toward systemic vaccinations. Thus, a lower dose of gb/gd was used periocularly (7.5 g of each glycoprotein per eye versus 25 g of each glycoprotein given systemically) and a lower dose of virus and fewer periocular vaccinations were given with HSV-1 KOS ( PFU/eye versus PFU systemically; two periocular vaccinations versus three systemic vaccinations). Because suboptimal vaccines were specifically chosen for these studies, even ocular vaccination did not always provide significant protection against eye disease. However, in all situations in which differences in ocular protection were detected between the systemic and periocular routes of vaccine, the local periocular vaccine was superior. As judged by neutralization and ELISA titers, both vaccines used in this study induced stronger humoral immune responses when the vaccine was delivered via a systemic route (i.m. or subcutaneous) than via an ocular route (topically on the cornea or subconjunctival injection). This finding suggests that in the rabbit ocular model of primary HSV-1 infection, the ability of a vaccine to induce serum neutralization titers and serum ELISA titers is not predictive of vaccine efficacy against eye disease and supports the hypothesis that vaccine efficacy against ocular disease is due to local/mucosal immunity and not systemic immunity. The ability of these vaccines to induce tear siga specific for HSV-1 also did not appear to be predictive of vaccine efficacy against eye disease. In fact, there was an opposite tendency. Systemic vaccination tended to produce higher peak tear siga titers than did the more efficacious ocular vaccination. Furthermore, the peak tear siga titers produced following ocular challenge of mock-vaccinated rabbits tended to be higher than in either vaccine group. This type of result, in which following ocular challenge, the highest local ocular immune response occurs in the least well protected group, suggests that the higher immune response is the result of more virus replication in the eye due to the poorer efficacy of the vaccine. This, of course, can complicate the correlation of specific immune responses with vaccine efficacy and was similar to some of our previous findings in mice, in which following ocular HSV-1 challenge, fewer infiltrating immune cells were detected in the corneas of mice vaccinated with the more efficacious vaccines (14). Interestingly, vaccine efficacy against mortality was similar Vaccine TABLE 3. Percent vaccine efficacy % Efficacy a Mortality b Conjunctivitis c Iritis c Clouding c Epithelial keratitis c KOS ocular KOS systemic d gb/gd ocular gb/gd systemic a Calculated as 1 (incidence rate in vaccine group/incidence rate in control group) 100. b Incidence rate is defined as percent mortality. c Incidence rate is defined as average severity on the day of peak average severity. d Less than 0% efficacy.
6 7720 NESBURN ET AL. J. VIROL. regardless of vaccine route. Thus, vaccine efficacy against eye disease appeared to require local or mucosal immune responses at the eye, while vaccine efficacy against mortality could be obtained by systemic immunity. Systemic immunity could protect against mortality (due to viral encephalitis) without reducing eye disease by reducing viral replication in the trigeminal ganglia or the brain, or by reducing transit of virus between the eye and the trigeminal ganglia or between the trigeminal ganglia and the brain. Various different immune responses have been implicated as being most important in protecting the mouse eye against HSV-1 infection. CD4 T cells and CD8 T cells have alternatively each been reported to protect against ocular HSV-1 and to be responsible for HSV-1 ocular disease (6, 13, 15, 16, 19, 27, 28, 33). In the mouse model, there is a very strong correlation between the ability of a vaccine to induce anti- HSV-1 serum antibody titers and vaccine efficacy against HSV-1 ocular infection (5, 12). Even intraperitoneal administration of neutralizing antibody can completely block HSV-1- induced ocular disease (18, 39). In contrast, in this report we did not find any correlation between serum antibody and protection against ocular disease in the rabbit. Serum antibody in humans also does not appear to protect against ocular HSV-1, since individuals with high rates of recurrent ocular HSV-1 often develop very high HSV-1 neutralizing antibody titers yet continue to have recurrent episodes. Thus, it appears that the immune responses (and vaccine efficacy) involved in protecting the mouse eye against HSV-1 may not be predictive of vaccine efficacy in humans. In particular, since serum antibody alone can protect the mouse eye against ocular HSV-1, using the mouse model as the sole basis of understanding vaccine efficacy against ocular HSV-1 may cause us to underestimate the importance of vaccine-induced local/mucosal immunity in humans. Thus, although the state of the art in rabbit immunology still lags significantly behind that of the mouse, the rabbit may be a more useful model for studying vaccine efficacy against primary and recurrent ocular HSV-1. Why does humoral immunity protect the mouse eye and not the rabbit or human eye against ocular HSV-1? One possibility is the smaller size of the mouse eye. In rabbits and humans, capillaries are seen only in the outer 1 mm of the cornea, effectively isolating the central cornea from circulating immune factors. In the mouse, capillaries are also confined to the outer 1 mm of the cornea. However, because the mouse cornea is smaller than the corneas of rabbits and humans, circulating immune factors can rapidly diffuse from these peripheral capillaries into the central cornea, thus allowing serum antibody to protect the mouse cornea. The ability to analyze cell-mediated immunity and ocular mucosal immune factors (other than tear siga) in the rabbit is still in its infancy compared to the situation for mice. Thus, the local/mucosal immune factors responsible for the vaccine efficacy against HSV-1-induced ocular disease in this study have not yet been determined. Although the siga analyses reported here suggest that tear siga is not a key protective immune response against primary HSV-1 ocular challenge, preliminary studies using a recurrent ocular HSV-1 vaccine model suggest that tear siga may play a role in protection against recurrent ocular HSV-1. ACKNOWLEDGMENTS We thank Anita Avery for excellent technical assistance, Jaleh Kilpatrick for measuring the serum ELISA antibody responses, and Philip Ng for measuring the neutralizing antibody responses. This work was partially supported by Public Health Service grant EYO9392, the Discovery Fund for Eye Research, the Skirball Program in Molecular Ophthalmology, and the Factor Family Foundation. REFERENCES 1. Bouley, D. M., S. Kanangat, and B. T. Rouse The role of the innate immune system in the reconstituted SCID mouse model of herpetic stromal keratitis. Clin. Immunol. Immunopathol. 80: Corey, L., and P. G. Spear Infections with herpes simplex viruses (1). N. Engl. J. Med. 314: Corey, L., and P. G. Spear Infections with herpes simplex viruses (2). N. Engl. J. Med. 314: Dawson, C. R., and B. Togni Herpes simplex eye infections: clinical manifestations, pathogenesis and management. Surv. Ophthalmol. 21: Ghiasi, H., S. Bahri, A. B. Nesburn, and S. L. Wechsler Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins. Investig. Ophthalmol. Visual Sci. 36: Ghiasi, H., S. Cai, A. B. Nesburn, and S. L. Wechsler MHC-II but not MHC-I responses are required for vaccine-induced protection against ocular challenge with HSV-1. Curr. Eye Res. 16: Ghiasi, H., S. Cai, A. B. Nesburn, and S. L. Wechsler Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection. Virology 224: Ghiasi, H., R. Kaiwar, A. B. Nesburn, S. Slanina, and S. L. Wechsler Baculovirus-expressed glycoprotein E (ge) of herpes simplex virus type-1 (HSV-1) protects mice against lethal intraperitoneal and lethal ocular HSV-1 challenge. Virology 188: Ghiasi, H., R. Kaiwar, A. B. Nesburn, and S. L. Wechsler Baculovirus expressed herpes simplex virus type 1 glycoprotein C protects mice from lethal HSV-1 infection. Antiviral Res. 18: Ghiasi, H., R. Kaiwar, A. B. Nesburn, and S. L. Wechsler Expression of herpes simplex virus type 1 glycoprotein B in insect cells. Initial analysis of its biochemical and immunological properties. Virus Res. 22: Ghiasi, H., R. Kaiwar, A. B. Nesburn, and S. L. Wechsler Expression of herpes simplex virus type 1 glycoprotein I in baculovirus: preliminary biochemical characterization and protection studies. J. Virol. 66: Ghiasi, H., A. B. Nesburn, and S. L. Wechsler Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine 14: Ghiasi, H., D. C. Roopenian, S. Slanina, S. Cai, A. B. Nesburn, and S. L. Wechsler The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Immunology 91: Ghiasi, H., S. L. Wechsler, R. Kaiwar, A. B. Nesburn, and F. M. Hofman Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1. J. Virol. 69: Hendricks, R. L., M. Janowicz, and T. M. Tumpey Critical role of corneal Langerhans cells in the CD4- but not CD8-mediated immunopathology in herpes simplex virus-1-infected mouse corneas. J. Immunol. 148: Hendricks, R. L., and T. M. Tumpey Concurrent regeneration of T lymphocytes and susceptibility to HSV-1 corneal stromal disease. Curr. Eye Res. 10: Hill, J. M., M. A. Rayfield, and Y. Haruta Strain specificity of spontaneous and adrenergically induced HSV-1 ocular reactivation in latently infected rabbits. Curr. Eye Res. 6: Keadle, T. L., K. A. Laycock, J. K. Miller, K. K. Hook, E. D. Fenoglio, M. Francotte, M. Slaoui, P. M. Stuart, and J. S. Pepose Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. J. Infect. Dis. 176: Kolaitis, G., M. Doymaz, and B. T. Rouse Demonstration of MHC class II-restricted cytotoxic T lymphocytes in mice against herpes simplex virus. Immunology 71: Langenberg, A. G., R. L. Burke, S. F. Adair, R. Sekulovich, M. Tigges, C. L. Dekker, and L. Corey A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. Ann. Intern. Med. 122: (Erratum, 123:395.) 21. Mertz, G. J., R. Ashley, R. L. Burke, J. Benedetti, C. Critchlow, C. C. Jones, and L. Corey Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J. Infect. Dis. 161: Nesburn, A. B. (ed.) Report of the corneal disease panel: vision research: a national plan , vol. II, part III. The C.V. Mosby Co., St. Louis, Mo. 23. Nesburn, A. B., R. L. Burke, H. Ghiasi, S. Slanina, S. Bahri, and S. L. Wechsler Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J. Virol. 68:
7 VOL. 72, 1998 PERIOCULAR VACCINATION AGAINST OCULAR HSV Nesburn, A. B., R. L. Burke, H. Ghiasi, S. M. Slanina, and S. L. Wechsler A therapeutic vaccine that reduces recurrent herpes simplex virus corneal disease. Investig. Ophthalmol. Visual Sci., 39: Nesburn, A. B., H. Ghiasi, and S. L. Wechsler Ocular safety and efficacy of an HSV-1 gd vaccine during primary and latent infection. Investig. Ophthalmol. Visual Sci. 31: Nesburn, A. B., C. Robinson, and R. Dickinson Adenine arabinoside effect on experimental idoxuridine-resistant herpes simplex infection. Investig. Ophthalmol. 13: a.Nesburn, A. B., and S. L. Wechsler. Unpublished observations. 27. Newell, C. K., S. Martin, D. Sendele, C. M. Mercadal, and B. T. Rouse Herpes simplex virus-induced stromal keratitis: role of T-lymphocyte subsets in immunopathology. J. Virol. 63: Newell, C. K., D. Sendele, and B. T. Rouse Effects of CD4 and CD8 T-lymphocyte depletion on the induction and expression of herpes simplex stromal keratitis. Regul. Immunol. 2: Perng, G. C., E. C. Dunkel, P. A. Geary, S. M. Slanina, H. Ghiasi, R. Kaiwar, A. B. Nesburn, and S. L. Wechsler The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J. Virol. 68: Perng, G. C., R. L. Thompson, N. M. Sawtell, W. E. Taylor, S. M. Slanina, H. Ghiasi, R. Kaiwar, A. B. Nesburn, and S. L. Wechsler An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation. J. Virol. 69: Rock, D. L., A. B. Nesburn, H. Ghiasi, J. Ong, T. L. Lewis, J. R. Lokensgard, and S. L. Wechsler Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J. Virol. 61: Rouse, B. T., S. Norley, and S. Martin Antiviral cytotoxic T lymphocyte induction and vaccination. Rev. Infect. Dis. 10: Russell, R. G., M. P. Nasisse, H. S. Larsen, and B. T. Rouse Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis. Investig. Ophthalmol. Visual Sci. 25: Sanchez-Pescador, L., R. L. Burke, G. Ott, and G. Van Nest The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J. Immunol. 141: Smith, R. E., H. R. McDonald, A. B. Nesburn, and D. S. Minckler Penetrating keratoplasty: changing indications, 1947 to Arch. Ophthalmol. 98: Stanberry, L. R., D. I. Bernstein, R. L. Burke, C. Pachl, and M. G. Myers Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect. Dis. 155: Stanberry, L. R., M. G. Myers, D. E. Stephanopoulos, and R. L. Burke Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy. J. Gen. Virol. 70: Stroop, W. G., and M. C. Banks Herpes simplex virus type 1 strain KOS-63 does not cause acute or recurrent ocular disease and does not reactivate ganglionic latency in vivo. Acta Neuropathol. (Berlin) 87: Walker, J., K. Laycock, J. Pepose, and D. Leib Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiationinduced ocular herpes virus shedding in mice. Vaccine 16:6 8. Downloaded from on November 21, 2018 by guest
A Therapeutic Vaccine That Reduces Recurrent Herpes Simplex Virus Type 1 Corneal Disease
A Therapeutic Vaccine That Reduces Recurrent Herpes Simplex Virus Type 1 Corneal Disease Anthony B. Nesburn, 1 ' 2 Rae Lyn Burke, 5 Homayon Ghiasi, 1 ' 2 Susan M. Slanina, 1 Steven L Wechsler 1 ' 2 and
More informationDisease caused by herpes simplex virus
Recurrence of herpes simplex virus in rabbit eyes: Results of a three-year study Peter R. Laibson and Sidney Kibrick Spontaneous reactivation of herpes simplex virus in rabbit ocular tissue was found on
More informationamounts of biologically functional and highly immunogenic glycoproteins (15-21). We vaccinated mice with an equal
JOURNAL OF VIROLOGY, Apr. 1994, p. 2118-2126 Vol. 68, No. 4 22-538X/94/$4.+ Copyright 1994, American Society for Microbiology Expression of Seven Herpes Simplex Virus Type 1 Glycoproteins (gb, gc, gd,
More informationOcular infection with HSV-1 causes eye disease ranging in
Role of Anti Glycoproteins D (Anti gd) and K (Anti gk) IgGs in Pathology of Herpes Stromal Keratitis in Humans Kevin R. Mott, 1 Yanira Osorio, 1 Ezra Maguen, 1 Anthony B. Nesburn, 2 Alec E. Wittek, 3,4
More informationThe Severity of Herpes Simplex Viral Keratitis in Mice Does Not Reflect the Severity of Disease in Humans
Investigative Ophthalmology & Visual Science, Vol. 33, No. 2, February 992 Copyright Association for Research in Vision and Ophthalmology The Severity of Herpes Simplex Viral Keratitis in Mice Does Not
More informationThe Effect of Immunization with Herpes Simplex Virus Glycoprotein D Fused with Interleukin-2 against Murine Herpetic Keratitis
The Effect of Immunization with Herpes Simplex Virus Glycoprotein D Fused with Interleukin-2 against Murine Herpetic Keratitis Tomoyuki Inoue*, Yoshitsugu Inoue*, Takao Nakamura*, Atsushi Yoshida*, Yumiko
More informationOverexpression of Interleukin-2 by a Recombinant Herpes Simplex Virus Type 1 Attenuates Pathogenicity and Enhances Antiviral Immunity
JOURNAL OF VIROLOGY, Sept. 2002, p. 9069 9078 Vol. 76, No. 18 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.18.9069 9078.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Overexpression
More informationfollowing ocular infection of naive mice with a recombinant HSV-1 expressing murine IL-4 Dhong Hyun Lee 1 and Homayon Ghiasi 1,*
JVI Accepted Manuscript Posted Online 28 February 2018 J. Virol. doi:10.1128/jvi.00051-18 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 2 An M2 rather than T H 2 response contributes
More informationEffect of acyclovir on acute and latent herpes simplex virus infections in the rabbit. Melvin D. Trousdale, Edmund C. Dunkel, and Anthony B.
Effect of acyclovir on acute and latent herpes simplex virus infections in the rabbit Melvin D. Trousdale, Edmund C. Dunkel, and Anthony B. Nesburn Acyclovir, a new potent antiviral drug, was used to treat
More informationIsolation of herpes simplex virus from the cornea in
British Journal of Ophthalmology, 1982, 66, 643-647 Isolation of herpes simplex virus from the cornea in chronic stromal keratitis C. SHIMELD, A. B. TULLO, D. L. EASTY, AND J. THOMSITT* From the Department
More informationRecovery of Herpes Simplex Virus From Oculor Tissues of Latently Infected Inbred Mice
Investigative Ophthalmology & Visual Science, Vol. 29, No. 2, February 1988 Copyright Association for Research in Vision and Ophthalmology Recovery of Herpes Simplex Virus From Oculor Tissues of Latently
More informationCondition: Herpes Simplex Keratitis
Condition: Herpes Simplex Keratitis Description: Herpes simplex infection is very common but usually remains latent. When the virus is reactivated it travels along the trigeminal nerve to cause local infection
More informationMutations within the pathogenic region of HSV-1 gk signal sequences alter cell surface. expression and neurovirulence.
JVI Accepts, published online ahead of print on 10 December 2014 J. Virol. doi:10.1128/jvi.03506-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Mutations within the pathogenic
More informationH erpes simplex virus infection of the
Herpes simplex keratitis An experimental study Samuel J. Kimura, Victor Diaz-Bonnet, and Masao Okumoto The incidence of complicated herpes simplex keratitis appears to have increased and the important
More informationHerpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry
Herpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry I have what?! How to break the news Meet the Herpes Quick virology
More informationVaricella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus
Varicella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus Helena M. Tabery Varicella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus In Vivo Morphology in the Human Cornea
More informationReactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion: an in vivo study of virus antigen and immune cell infiltration
Journal of General Virology (1996), 77, 2583-259. Printed in Great Britain Reactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion: an in vivo study of virus antigen and immune cell
More informationChronic Infections by Herpes Simplex Viruses and by the Horse and Cat Herpesviruses
INFECTION AND IMMUNITY, Apr. 70, p. 351-355 Copyright 70 American Society for Microbiology Vol. 1, No. 4 Printed in U.S.A. Chronic Infections by Herpes Simplex Viruses and by the Horse and Cat Herpesviruses
More informationClass-Specific Antibody Response in Acyclovir- Treated and Adenine Arabinoside-Treated Patients with Primary Genital Herpes Simplex Virus Infection
Microbiol. Immunol., 39(10), 795-799, 1995 Class-Specific Antibody Response in Acyclovir- Treated and Adenine Arabinoside-Treated Patients with Primary Genital Herpes Simplex Virus Infection Takashi Kawana*,1,
More informationLab 3: Pathogenesis of Virus Infections & Pattern 450 MIC PRACTICAL PART SECTION (30397) MIC AMAL ALGHAMDI 1
Lab 3: Pathogenesis of Virus Infections & Pattern 450 MIC PRACTICAL PART SECTION (30397) 2018 450 MIC AMAL ALGHAMDI 1 Learning Outcomes The pathogenesis of viral infection The viral disease pattern Specific
More informationWith a staggering one billion individuals worldwide
Immunology and Microbiology A Herpes Simplex Virus Type 1 Human Asymptomatic CD8 þ T-Cell Epitopes-Based Vaccine Protects Against Ocular Herpes in a Humanized HLA Transgenic Rabbit Model Ruchi Srivastava,
More informationTrifluridine Ophthalmic Solution, 1% Sterile
Trifluridine Ophthalmic Solution, 1% Sterile DESCRIPTION Trifluridine (also known as trifluorothymidine, F 3 TdR,F 3 T), is an antiviral drug for topical treatment of epithelial keratitis caused by herpes
More informationSpread of Virus and Distribution of Latent Infection Following Ocular Herpes Simplex in the Non-immune and Immune Mouse
J. gen. Virol. (1982), 63, 95-101. Printed in Great Britain Key words: ocular HSV/latent infection/trigeminal ganglion 95 Spread of Virus and Distribution of Latent Infection Following Ocular Herpes Simplex
More informationCURRICULUM VITAE Shahla Z. Abghari
Shahla Z. Abghari, Ph. D. Updated March 4, 2014 PAGE 1 CURRICULUM VITAE Shahla Z. Abghari U. S. CITIZENSHIP: April 1992 EDUCATION: 1966-1970 B.S., Biology, Teachers University, Tehran, Iran 1967-1971 B.A.,
More informationCharacterization of a Murine Model of Recurrent Herpes Simplex Viral Keratitis Induced by Ultraviolet B Radiation
Investigative Ophthalmology & Visual Science, Vol. 32, No. 10, September 1991 Copyright Association for Research in Vision and Ophthalmology Characterization of a Murine Model of Recurrent Herpes Simplex
More informationImmune cell infiltration in corneas of mice with recurrent herpes simplex virus disease
Journal of General Virology (199), 77, 97~95. Printed in Great Britain 977 Immune cell infiltration in corneas of mice with recurrent herpes simplex virus disease Carolyn Shimeld,* Joanne L. Whiteland,
More informationHerpes simplex virus infections of the eye and their management with acyclovir
Journal of Antimicrobial Chemotherapy (1983) 12, Suppl. B, 39-43 Herpes simplex virus infections of the eye and their management with acyclovir M. G. Falcon Eye Department, St Thomas' Hospital, London
More informationAcute and Recurrent Herpes Simplex in Several Strains of Mice
J. gen. Virol. (1981), 55, 31-40. Printed in Great Britain 31 Key words: herpes simplex~mice~latency~recurrence Acute and Recurrent Herpes Simplex in Several Strains of Mice By D. A. HARBOUR, T. J. HILL
More informationVIROPTIC Ophthalmic Solution, 1% Sterile (trifluridine ophthalmic solution)
VIROPTIC Ophthalmic Solution, 1% Sterile (trifluridine ophthalmic solution) PRODUCT OVERVIEW: VIROPTIC SOLUTION DESCRIPTION VIROPTIC is the brand name for trifluridine (also known as trifluorothymidine,
More informationHerpes Simplex Virus Virion Host Shutoff (vhs) Activity Alters Periocular Disease in Mice
JOURNAL OF VIROLOGY, Apr. 2000, p. 3598 3604 Vol. 74, No. 8 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Herpes Simplex Virus Virion Host Shutoff (vhs)
More informationHSV LAT AND NEURONAL SURVIVAL
International Reviews of Immunology, 23: 187 198, 2004 Copyright # Taylor & Francis Inc. ISSN: 0883-0185 print/1563-5244 online DOI: 10.1080=08830180490265592 HSV LAT AND NEURONAL SURVIVAL DAVID C. BLOOM
More informationVaccine Therapy for Ocular Herpes Simplex Virus (HSV) Infection:
JOURNAL OF VIROLOGY, Aug. 1994, p. 584-592 Vol. 68, No. 8 22-538X/94/$4.+ Copyright 1994, Aerican Society for Microbiology Therapy for Ocular Herpes Siplex Virus (HSV) Infection: Periocular Vaccination
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More informationClinical Profile of Herpes Simplex Keratitis
K V Raju MS, Jyothi PT MS, Shimna Iqbal MS Clinical Profile of Herpes Simplex Keratitis Original Article Abstract Aims To document the various clinical presentations and to assess the risk factors contributing
More informationQ: (picture of typical dendrite) What is the differential diagnosis and describe this entity? How would you treat and why?
Q: (picture of typical dendrite) What is the differential diagnosis and describe this entity? How would you treat and why? Etiology/Risks: Critical symptoms: HSV is transmitted by direct contact of epidermis
More informationIn Vivo Reactivation of Herpes Simplex Virus in Rabbit Trigeminal Ganglia: Electrode Model
INFECTION AND IMMUNITY, Oct. 1981, p. 69-74 0019-9567/81/100069-06$02.00/0 Vol. 34, No. 1 In Vivo Reactivation of Herpes Simplex Virus in Rabbit Trigeminal Ganglia: Electrode Model MARY T. GREEN,`* JOHN
More informationSubunit adjuvanted zoster vaccine: why the fuss?
Subunit adjuvanted zoster vaccine: why the fuss? Soren Gantt, MD PhD MPH Pediatric Infectious Diseases Vaccine Evaluation Center BC Children s Hospital University of British Columbia Disclosures Research
More informationHerpes Simplex Viruses: Disease Burden. Richard Whitley The University of Alabama at Birmingham Herpes Virus Infection and Immunity June 18-20, 2012
Herpes Simplex Viruses: Disease Burden Richard Whitley The University of Alabama at Birmingham Herpes Virus Infection and Immunity June 18-20, 2012 Mucocutaneous HSV Infections Life-Threatening HSV Diseases
More informationKoppolu Sreedhar Reddy 1* and Venkata Prasanna DP 2
e - ISSN - 2349-8005 INTERNATIONAL JOURNAL OF ADVANCES IN CASE REPORTS Journal homepage: www.mcmed.us/journal/ijacr EFFICACY OF TOPICAL ACYCLOVIR IN TREATMENT OF HERPETIC KERATITIS Koppolu Sreedhar Reddy
More informationOCULAR HERPES simplex virus
CLINICAL SCIENCES Oral Acyclovir After Penetrating Keratoplasty for Herpes Simplex Keratitis Fabiana P. Tambasco, MD; Elisabeth J. Cohen, MD; Lien H. Nguyen, MD; Christopher J. Rapuano, MD; Peter R. Laibson,
More informationProphylactic HPV Vaccines. Margaret Stanley Department of Pathology Cambridge
Prophylactic HPV Vaccines Margaret Stanley Department of Pathology Cambridge 8kb double stranded DNA viruses, absolutely host and tissue specific, Can t grow virus in tissue culture Classified by genotype
More informationAlphaherpesvirinae. Simplexvirus (HHV1&2/ HSV1&2) Varicellovirus (HHV3/VZV)
Alphaherpesvirinae Simplexvirus (HHV1&2/ HSV1&2) Varicellovirus (HHV3/VZV) HERPES SIMPLEX VIRUS First human herpesvirus discovered (1922) Two serotypes recognised HSV-1 & HSV-2 (1962) HSV polymorphism
More informationNature Immunology: doi: /ni Supplementary Figure 1. Production of cytokines and chemokines after vaginal HSV-2 infection.
Supplementary Figure 1 Production of cytokines and chemokines after vaginal HSV-2 infection. C57BL/6 mice were (a) treated intravaginally with 20 µl of PBS or infected with 6.7x10 4 pfu of HSV-2 in the
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationInterferons Regulate the Phenotype of Wild-type and Mutant Herpes Simplex Viruses In Vivo
Published Online: 15 February, 1999 Supp Info: http://doi.org/10.1084/jem.189.4.663 Downloaded from jem.rupress.org on July 4, 2018 Interferons Regulate the Phenotype of Wild-type and Mutant Herpes Simplex
More informationRadioimmunoassay of Herpes Simplex Virus Antibody: Correlation with Ganglionic Infection
J. gen. Virol. (I977), 3 6, ~ 371-375 Printed in Great Britain 371 Radioimmunoassay of Herpes Simplex Virus Antibody: Correlation with Ganglionic Infection By B. FORGHANI, TONI KLASSEN AND J. R. BARINGER
More informationReview Article Understanding the Role of Chemokines and Cytokines in Experimental Models of Herpes Simplex Keratitis
Hindawi Immunology Research Volume 2017, Article ID 7261980, 5 pages https://doi.org/10.1155/2017/7261980 Review Article Understanding the Role of Chemokines and Cytokines in Experimental Models of Herpes
More informationHerpesviruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics
Herpesviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Enveloped icosahedral capsid (T=16), diameter 125 nm Diameter of enveloped virion 200 nm Capsid
More informationSHEDDING OF BHV1 AFTER EXPERIMENTAL CONJUNCTIVAL INOCULATION AND AFTER THE REACTIVATION OF LATENT INFECTION IN RABBITS
Bull. Vet. Inst. Pulawy 7, 0-0, 00 SHEDDING OF BHV AFTER EXPERIMENTAL ONJUNTIVAL INOULATION AND AFTER THE REATIVATION OF LATENT INFETION IN RABBITS JERZY ROLA, MIROSŁAW P. POLAK AND JAN F. MUDZISKI Department
More informationOcular Infection With Herpes Simplex Virus in Several Strains of Rat
Ocular Infection With Herpes Simplex Virus in Several Strains of Rat Susan M. Nicholls,* Amina Benylles,* Carolyn Shimeld,* David L. Easty,\ and Terry ]. Hill% Purpose. To assess the suitability of the
More informationPathogenesis of Herpes Simplex Virus Type 1-Induced Corneal Inflammation in Perforin-Deficient Mice
JOURNAL OF VIROLOGY, Dec. 2000, p. 11832 11840 Vol. 74, No. 24 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Pathogenesis of Herpes Simplex Virus Type 1-Induced
More informationDr Jo-Anne Pon. Dr Sean Every. 8:30-9:25 WS #70: Eye Essentials for GPs 9:35-10:30 WS #80: Eye Essentials for GPs (Repeated)
Dr Sean Every Ophthalmologist Southern Eye Specialists Christchurch Dr Jo-Anne Pon Ophthalmologist Southern Eye Specialists, Christchurch Hospital, Christchurch 8:30-9:25 WS #70: Eye Essentials for GPs
More informationD. 'endritic corneal lesions were considered
Varicella dendritic keratitis* Anthony B. Nesburn, Adam Bonl,** John Pentelei-Molnar, and Richard Lazaro Atypical dendritic keratitis has been described following herpes zoster infection. This is the first
More informationComparison of Herpes Simplex Virus Reactivation in Ganglia In Vivo and in Explants Demonstrates Quantitative and Qualitative Differences
JOURNAL OF VIROLOGY, July 2004, p. 7784 7794 Vol. 78, No. 14 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.14.7784 7794.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Comparison
More informationLearning Objectives:
Viral keratitis and antivirals Learning Objectives: Recognise and distinguish different types of viral keratitis HSV HZO Adenovirus Discuss the use of antiviral agents in the treatment of herpetic infections
More informationAntivirals and Vaccines: What s old and new in HSV-2 treatment
Antivirals and Vaccines: What s old and new in HSV-2 treatment Christine Johnston, MD, MPH Last Updated: January 19, 2018 uwptc@uw.edu uwptc.org 206-685-9850 Importance of HSV: Why pursue a vaccine? Prevention
More informationGanciclovir-resistant CMV retinitis in a patient with wild-type plasma CMV. North Carolina School of Medicine, Chapel Hill, NC
JCM Accepts, published online ahead of print on 15 February 2012 J. Clin. Microbiol. doi:10.1128/jcm.00029-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Ganciclovir-resistant
More informationWhat are some common conditions that affect the cornea?
What are some common conditions that affect the cornea? Injuries After minor injuries or scratches, the cornea usually heals on its own. Deeper injuries can cause corneal scarring, resulting in a haze
More informationHerpes Simplex Virus Type 1 and Alzheimer s disease:
The Neurodegenerates Herpes Simplex Virus Type 1 and Alzheimer s disease: Increasing Evidence for a major role of the virus 1 Introduction and Agenda 2 Agenda What is the HSV1 and why is it linked to AD?
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationThe humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
More informationB eyond individual benefits, the public health significance
24 ORIGINAL ARTICLE The potential epidemiological impact of a genital herpes vaccine for women G P Garnett, G Dubin, M Slaoui, T Darcis... See end of article for authors affiliations... Correspondence
More informationStructure of viruses
Antiviral Drugs o Viruses are obligate intracellular parasites. o lack both a cell wall and a cell membrane. o They do not carry out metabolic processes. o Viruses use much of the host s metabolic machinery.
More informationPERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES
71 PERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES Harold G. Jensen, Alan J. Parkinson, and L. Vernon Scott* Department of Microbiology & Immunology, University of Oklahoma
More informationElucidating the protective and pathologic T cell species in the virus-induced corneal immunoinflammatory condition herpetic stromal keratitis
Elucidating the protective and pathologic T cell species in the virus-induced corneal immunoinflammatory condition herpetic stromal keratitis Kaustuv Banerjee, Partha Sarathi Biswas, and Barry T. Rouse
More informationHERPES SIMPLEX VIRUS (HSV)
CLINICAL SCIENCES Modalities to Decrease Stromal Herpes Simplex Keratitis Reactivation Rates John D. Sheppard, MD; Michael L. Wertheimer, MD; Stephen V. Scoper, MD Objective: To evaluate the efficacy of
More informationSummary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies
Summary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies Genital herpes is one of the most prevalent sexually transmitted diseases, affecting more than one in five sexually active
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationContribution of Virus ond Immune Factors to Herpes Simplex Virus Type l-lnduced Corneal Pathology
October 1990 Vol. 31/10 Investigative Ophthalmology & Visual Science Articles Contribution of Virus ond Immune Factors to Herpes Simplex Virus Type l-lnduced Corneal Pathology Robert L. Hendricks and Terrence
More informationThe Latent Herpes Simplex Virus Type 1 Genome Copy Number in Individual Neurons Is Virus Strain Specific and Correlates with Reactivation
JOURNAL OF VIROLOGY, July 1998, p. 5343 5350 Vol. 72, No. 7 0022-538X/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. The Latent Herpes Simplex Virus Type 1 Genome Copy
More informationCORNEAL DENDRITE. What else do you want to know about this patient? What would be your initial treatment?
Viral Keratitis CORNEAL DENDRITE What else do you want to know about this patient? What would be your initial treatment? Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes
More informationSPECIFIC ANTIINFECTIOUS IMMUNITY. colostral immunity. administration of antibodies VIRULENT VACCINE INACTIVATED VACCINE
INDUCTION OF IMMUNITY AGAINST INFECTION SPECIFIC ANTIINFECTIOUS IMMUNITY active passive S AND VACCINATION infection vaccination colostral immunity administration of antibodies VIRULENT MODIFIED LIVE INACTIVATED
More informationCORNEAL CONDITIONS CORNEAL TRANSPLANTATION
GENERAL INFORMATION CORNEAL CONDITIONS CORNEAL TRANSPLANTATION WHAT ARE CORNEAL CONDITIONS? The cornea is the clear outer layer of the eye. Shaped like a dome, it helps to protect the eye from foreign
More informationHerpesviruses. -Recurrence: clinically obvious disease due to reactivation. **Reactivation and recurrence are used interchangeably.
*Herpesviruses: A large group of viruses (100 strains), but we are concerned with only 8 strains as they are the only ones to infect human beings *herpesviruses groups: HSV-1 HSV-2 VZV CMV EBV HHV-6 HHV-7
More informationProspects for Control of Herpes Simplex Virus Disease through Immunization
549 REVIEW ARTICLE Prospects for Control of Herpes Simplex Virus Disease through Immunization Lawrence R. Stanberry, 1 Anthony L. Cunningham, 4 Adrian Mindel, 5 Laurie L. Scott, 2 Spotswood L. Spruance,
More informationRole of Dendritic Cells in Enhancement of Herpes Simplex Virus Type 1 Latency and Reactivation in Vaccinated Mice
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2008, p. 1859 1867 Vol. 15, No. 12 1556-6811/08/$08.00 0 doi:10.1128/cvi.00318-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Role of Dendritic
More informationConjunctivitis in Cats
Customer Name, Street Address, City, State, Zip code Phone number, Alt. phone number, Fax number, e-mail address, web site Conjunctivitis in Cats (Inflammation of the Moist Tissues of the Eye) Basics OVERVIEW
More informationPossible latent infection with herpes simplex virus in the mouse eye
Journal of General Virology (1990), 71, 2385-2390. Printed in Great Britain 2385 Possible latent infection with herpes simplex virus in the mouse eye C. M. P. Claou~,l*1 " T. J. Hodges, 1 J. M. Darville,
More informationMedChem401 Herpesviridae. Herpesviridae
MedChem401 Herpesviridae Members of the herpesvirus family have been identified in more than 80 different animal species Eight have been identified as human pathogens Herpes viruses are a leading cause
More informationNearly 45 million persons in the United States
THERAPEUTICS FOR THE CLINICIAN A Double-Blind Study of the Efficacy and Safety of the ICP10 PK Vaccine Against Recurrent Genital HSV-2 Infections Gerardo Casanova, MD; Rosalia Cancela, MD; Lourdes Alonzo,
More informationHerpes viruses. Dr.farah hazem. Classification:
Dr.farah hazem Herpes viruses Herpesviridae are a large family of viruses contains several of the most important human viral pathogens. Clinically, the herpesviruses exhibit a spectrum of diseases. Some
More informationAcute Retinal Necrosis Secondary to Varicella Zoster Virus in an Immunosuppressed Post-Kidney Transplant Patient
CM&R Rapid Release. Published online ahead of print September 20, 2012 as Aperture Acute Retinal Necrosis Secondary to Varicella Zoster Virus in an Immunosuppressed Post-Kidney Transplant Patient Elizabeth
More informationImmunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008
Immunity to Viruses Patricia Fitzgerald-Bocarsly September 25, 2008 The Immune System Deals with a Huge Range of Pathogens Roitt, 2003 Immune Responses to Viruses Viruses are dependent on the host cell
More informationT Lymphocytes in the Trigeminal Ganglia of Rabbits During Corneal HSV Infection
Investigative Ophthalmology & Visual Science, Vol. 29, No. 11, November 1988 Copyright Association for Research in Vision and Ophthalmology T Lymphocytes in the Trigeminal Ganglia of Rabbits During Corneal
More informationTesting for Herpes Simplex Infections Getting it DONE!
Testing for Herpes Simplex Infections Getting it DONE! Tens of millions of people have been diagnosed with herpes infections Genital Herpes Issues The Most Common Cause of Genital Ulceration is is Herpes
More informationPersistent Infections
Persistent Infections Lecture 17 Biology 3310/4310 Virology Spring 2017 Paralyze resistance with persistence WOODY HAYES Acute vs persistent infections Acute infection - rapid and self-limiting Persistent
More informationof HSV-1 infected rabbits
_~~~~~~~~~~ 644 ORIGINAL ARTICLES Department of Pathology, the Medical School, University of Bristol, Bristol for latency, it C Lynas N J Maitland Correspondence to: Dr S D Cook, Bristol Eye Hospital,
More informationmaking LT protection safer and easier
making LT protection safer and easier 1 vaccine up to 3 immunities 4 Vectormune FP-LT and. Vectormune FP-LT is a genetically engineered live fowl pox virus vaccine carrying 2 immunorelevant genes from
More informationAPPENDIX II: Corneal Penetration and Median Effective Dose of Antiviral Agents
APPENDIX II: Corneal Penetration and Median Effective Dose of Antiviral Agents Median Effective Dose (ED50) The median effective dose is a statistically derived dose of drug expected to produce a certain
More informationReducing the Sexual Transmission of Genital Herpes
CLINICAL GUIDELINE Reducing the Sexual Transmission of Genital Herpes Compiled by Adrian Mindel Introduction People diagnosed with genital herpes usually have many questions and concerns, a key one being
More informationReactivation of Herpes Simplex Virus Type 1 in the Mouse Trigeminal Ganglion: an In Vivo Study of Virus Antigen and Cytokines
JOURNAL OF VIROLOGY, Mar. 1999, p. 1767 1773 Vol. 73, No. 3 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Reactivation of Herpes Simplex Virus Type 1 in
More informationHerpes simplex virus type (HSV)-1 remains one of the most
Protective Immunity against Ocular Herpes Infection and Disease Induced by Highly Immunogenic Self- Adjuvanting Glycoprotein D Lipopeptide Vaccines Ilham Bettahi, 1 Anthony B. Nesburn, 1 Susan Yoon, 1
More informationNatural infection with herpes simplex virus type 1 (HSV-1) induces humoral and T cell responses to the HSV-1 glycoprotein H: L complex
Journal of General Virology (2000), 81, 2011 2015. Printed in Great Britain... SHORT COMMUNICATION Natural infection with herpes simplex virus type 1 (HSV-1) induces humoral and T cell responses to the
More informationNOTES. Role for Gamma Interferon in Control of Herpes Simplex Virus Type 1 Reactivation
JOURNAL OF VIROLOGY, Apr. 1999, p. 3418 3423 Vol. 73, No. 4 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. NOTES Role for Gamma Interferon in Control of Herpes
More informationEfficacy of Tear Eosinophil Cationic Protein Level Measurement Using Filter Paper for Diagnosing Allergic Conjunctival Disorders
Efficacy of Tear Eosinophil Cationic Protein Level Measurement Using Filter Paper for Diagnosing Allergic Conjunctival Disorders Jun Shoji*, Minoru Kitazawa*, Noriko Inada*, Mitsuru Sawa*, Tetsuya Ono,
More informationINVELTYS (loteprednol etabonate ophthalmic suspension) 1%, for topical ophthalmic use Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INVELTYS safely and effectively. See full prescribing information for INVELTYS. INVELTYS (loteprednol
More informationHistory. Examination. Diagnosis/Course
History A 51 year-old female with a history of chronic dry eyes and photosensitivity was referred for evaluation. She reported a five year history of symptoms of frequent irritation and photophobia in
More informationPrevention of infection 2 : immunisation. How infection influences the host : viruses. Peter
Prevention of infection 2 : immunisation How infection influences the host : viruses Peter Balfe, p.balfe@bham.ac.uk @pbalfeuk Let s have some LO s just for fun 1. Define the Immune response to viruses,
More informationViroptic (trifluridine) solution [Monarch Pharmaceuticals, Inc.]
Viroptic (trifluridine) solution [Monarch Pharmaceuticals, Inc.] Description VIROPTIC is the brand name for trifluridine (also known as trifluorothymidine, F3TdR,F3T), an antiviral drug for topical treatment
More information